1\. Patients with chronic obstructive pulmonary disease based on GOLD diagnostic criteria;
2\. Age range from 40 to 85 years old (including 40 and 85 years old);
3\. BMI ≤ 35kg/m2;
4\. 15% ≤ FEV1% pred ≤ 45%;
5\. TLC\>100% pred, RV\>140% pred, and DLCO/red% ≥ 20%;
6\. 100m ≤ 6WMD ≤ 500m after rehabilitation training;
7\. Quit smoking for more than 4 months;
8\. The evaluation result of pulmonary bypass ventilation function is negative;
9\. Participants in this clinical trial requires the signing of an informed consent form by the individual or legal representative.
You may not be if
1\. Being pregnant or breastfeeding;
2\. PaCO2\>50mmHg and/or PaO2\<45mmHg;
3\. Obvious bronchiectasis or other infectious lung diseases;
4\. Hospitalization due to pulmonary infection or acute exacerbation of COPD within the past 12 months prior to baseline assessment twice or more times;
6\. Myocardial infarction or congestive heart failure within the past 24 weeks;
7\. Previous lobectomy, LVRS or lung transplantation;
8\. Anticoagulant therapy that cannot be stopped before surgery;
9\. Uncontrolled pulmonary arterial hypertension (systolic pulmonary arterial pressure\>45mmHg) or lungs diagnosed within the past 12 weeks Arterial hypertension;
10\. Left ventricular ejection fraction (LVEF) within the past 12 weeks is less than 45%;
11\. Pulmonary nodules that require intervention;
12\. Patients participating in other clinical trials;
13\. Individuals with other contraindications to bronchial operations;
14\. Other circumstances that the researcher deems unsuitable for participation in this clinical trial.
Clareo Health | Safety and Efficacy of Endobronchial Valve for Bronchoscopic Lung Volume Reduction Surgery: a Prospective Pilot Study
